The results of these studies should pave the way for a new era in thyroid cancer therapy, in which the genetic basis of tumor development is used to tailor the best treatment for each patient.

Patients with BRAF V600E-mutated metastatic colorectal cancer experienced improved responses when treated with Braftovi plus Erbitux and mFOLFOX6.

Pfizer's Braftovi combination showed significant survival benefits in a Phase 3 study for BRAF V600E-mutant metastatic ...

Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the ...

Pfizer’s metastatic colorectal cancer (mCRC) combination therapy has met one of the primary endpoints of improving ...

Without releasing specific figures, Pfizer said Monday that treatment ... BRAF V600E mutation, which can lead to activation of signaling pathways that drive certain cancers, including colorectal ...

FDA approved for the treatment of metastatic melanoma harboring activating BRAF mutations in August, 2011. Vemurafenib is metabolized by cytochrome P450 isoenzymes (predominantly CYP3A4 ...

The BRAF Inhibitors market is expected to grow significantly in the coming years. This is due to the increasing number of patients being diagnosed with cancer, rise in biomarker testing rates, the ...

representing a doubling of the odds of achieving an objective response BRAFTOVI combination regimen is the first and only targeted therapy approved by the U.S. FDA for treatment-naïve patients with ...

Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 ...